ArticleFuture virology2011
Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.
Article in Future virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- A Global Health Alert on the Re-Emergence of Mpox a Viral Zoonotic Illness Its Prevention and Management: A Narrative Review.Health science reports · 2026Article
- Cellular lipids: fundamental host factors for monkeypox virus replication and pathogenesis.Archives of microbiology · 2026Review
- Tecovirimat-Related Substance: Characterization, Hirshfeld Analysis, Theoretical Study, In Silico Toxicity Assessment.Molecules (Basel, Switzerland) · 2026Article
- Review
- Identification of a novel ectromelia virus from rodent: Implications for use as an in vivo infection model for vaccine and antiviral research.Virologica Sinica · 2025Article
- Monkeypox: Prevention Strategies and Challenges: Updated Review.Health science reports · 2025Article
- Monkeypox: a re-emergent virus with global health implications - a comprehensive review.Tropical diseases, travel medicine and vaccines · 2025Review
- Monkeypox: Origin, Transmission, Clinical Manifestations, Prevention, and Therapeutic Options.Interdisciplinary perspectives on infectious diseases · 2025Review
- Review
- The Effects of the Combined Co-Expression of GroEL/ES and Trigger Factor Chaperones on Orthopoxvirus Phospholipase F13 Production inBiotech (Basel (Switzerland)) · 2024Article
- Smallpox lesion characterization in placebo-treated and tecovirimat-treated macaques using traditional and novel methods.PLoS pathogens · 2024Article
- Clinical considerations on monkeypox antiviral medications: An overview.Pharmacology research & perspectives · 2024Review
- Type I Interferon: Monkeypox/Mpox Viruses Achilles Heel?Advances in experimental medicine and biology · 2024Review
- Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review.Life (Basel, Switzerland) · 2023Review
- Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging Human Monkeypox Virus.Journal of microbiology and biotechnology · 2023Review
- Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents.Microbiology spectrum · 2023Article
- Identification ofMicrobiology spectrum · 2023Article
- Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016-2022).Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Naturally occurring smallpox has been eradicated, yet it remains as one of the highest priority pathogens due to its potential as a biological weapon. The majority of the US population would be vulnerable in a smallpox outbreak. SIGA Technologies, Inc. has responded to the call of the US government to develop and supply to the Strategic National Stockpile a smallpox antiviral to be deployed in the event of a smallpox outbreak. ST-246(®) (tecovirimat) was initially identified via a high-throughput screen in 2002, and in the ensuing years, our drug-development activities have spanned in vitro analysis, preclinical safety, pharmacokinetics and efficacy testing (all according to the 'animal rule'). Additionally, SIGA has conducted Phase I and II clinical trials to evaluate the safety, tolerability and pharmacokinetics of ST-246, bringing us to our current late stage of clinical development. This article reviews the need for a smallpox therapeutic and our experience in developing ST-246, and provides perspective on the role of a smallpox antiviral during a smallpox public health emergency.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.